Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
Efficient Catalytic Hydrogenation of N-Unsubstituted Cyclic Imides to Cyclic Amines
作者:Anna M. Maj、Isabelle Suisse、Nathalie Pinault、Nicolas Robert、Francine Agbossou-Niedercorn
DOI:10.1002/cctc.201402233
日期:2014.9
The hydrogenation of N‐unsubstituted cyclicimides to the corresponding cyclic amines has been performed selectively with heterogeneous catalysts obtained from rhodium and molybdenum carbonyl precursors. Various substrates were reduced in good to high yields and selectivities. Platinum‐based catalysts also proved to be efficient. Furthermore, gram‐scale experiments were performed and the catalysts
[EN] NOVEL METHOD FOR PREPARING CIS-OCTAHYDRO-ISOINDOLE<br/>[FR] NOUVEAU PROCEDE DE PREPARATION DU CIS-OCTAHYDRO-ISOINDOLE
申请人:SERVIER LAB
公开号:WO2005030719A1
公开(公告)日:2005-04-07
Procédé de synthèse du cis-octahydro-isoindole à partir de phtalimide. Application à la synthèse de l'acide 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl) butyrique, de ses sels pharmaceutiquement acceptables et de ses hydrates.
Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
申请人:Chen Ping
公开号:US20070004733A1
公开(公告)日:2007-01-04
The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.